Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Jerez De La Frontera – page 5

129 clinical trials in Jerez De La Frontera, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Jerez De La Frontera at a glance
129
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

129 trials in Jerez De La Frontera

Open in trial search

Non-small cell lung cancer

Recruiting

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Ovarian cancer

Recruiting

Study of Paclitaxel, Carboplatin, and Bevacizumab with Niraparib for Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer After Surgery

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Arcagy Gineco

Chronic rhinosinusitis with nasal polyps

Recruiting

Study on Mepolizumab and Nasal Polypectomy for Patients with Chronic Rhinosinusitis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Mepolizumab
  • Sponsor:Instituto De Investigacion Marques De Valdecilla

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Breast cancer

Recruiting

Long-Term Study on Early Stage Breast Cancer Patients Using Capecitabine, Gemcitabine, and Paclitaxel

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Immunisation+3

Not yet recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:Sanofi Pasteur Inc.

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Not yet recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Mite allergy

Not yet recruiting

Efficacy and safety of house dust mite allergoid (Dermatophagoides farinae, D. pteronyssinus, aluminium hydroxide) in people with moderate to severe house dust mite allergy

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Aluminium Hydroxide

Asthma

Not yet recruiting

Long‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Kymera Therapeutics Inc.

Pre-eclampsia

Not yet recruiting

Acetylsalicylic Acid for Preventing Preeclampsia in Pregnant Women

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Embolism

Not yet recruiting

A study to evaluate the effectiveness of REGN7508 for preventing blood clots in adults with solid tumors undergoing cancer treatment.

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:REGN7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Non-small cell lung cancer

Not yet recruiting

Testing OMTX705 Combined with Carboplatin, Pemetrexed, and Tislelizumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Carboplatin
  • Sponsor:Oncomatryx Biopharma S.A.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Jerez De La Frontera

What the registry says about research in the country

01 Respiratory Medicine

Clinical trials focusing on various respiratory conditions including Acute Respiratory Distress Syndrome, chronic rhinosinusitis, and asthma. Research initiatives are exploring new therapeutic approaches for both adult and pediatric patients.

  • Asthma management in children and adults
  • Nasal polyps treatment evaluation
  • ARDS therapeutic interventions

Studies include testing of novel antibodies and investigating symptom improvement in chronic conditions.

02 Oncology Research

Comprehensive studies targeting various cancer types, with particular focus on breast cancer and lung cancer. Investigations include innovative treatment combinations and targeted therapies.

  • Advanced breast cancer treatments
  • Non-small cell lung cancer therapies
  • Bladder cancer interventions

Research emphasizes personalized treatment approaches and novel drug combinations.

03 Cardiovascular Studies

Research focusing on coronary artery disease and related conditions. Studies evaluate various therapeutic approaches including antiplatelet treatments and surgical interventions.

  • Coronary artery treatments
  • Antiplatelet therapy optimization
  • Arterial dissection management

Trials aim to improve treatment outcomes and reduce complications in cardiac patients.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.